The 2018 OMS report marked a before and after in the legal and sanitary consideration of CBD worldwide.
📷 AECANI Visual Lab
Conclusion of OMS
The report emphasizes that it is a safe substance for human consumption.
Key points of the report
The OMS report details that:
- The CBD does not produce the psychotropic effects typical of THC
- There is no evidence of public health problems associated with the use of pure CBD
- It has an excellent safety profile with minimal and manageable side effects
Non-audit recommendation
Based on these findings, the OMS formally recommended to the United Nations:
"Substances containing predominantly CBD and less than 0.2% THC should not be under international drug control.
The WHO recommends a health and evidence-based approach for the evaluation of substances.
📷 AECANI Visual Lab
Global Impact
This recommendation was the first step towards the reclassification of cannabis and its derivatives in the international conventions, recognizing the difference between drug and supplement/medication.
Current Regulatory Context
The WHO conclusions provide a relevant framework for regulatory processes such as that of ANSES, whose classification proposal is based on a methodology that merits comparative analysis.
Consideration
The WHO conclusions provide a relevant scientific basis that deserves to be considered in regulatory processes, alongside the available evidence on the safety profile of CBD.
📚 References
- OMS (2018) - Critical Review Report: Cannabidiol (CBD). Expert Committee on Drug Dependence
- United Nations (2020) - Reclassification of cannabis in the 1961 Convention